NCT03785197

Brief Summary

The purpose of the study is a scientific and prospective documentation of the clinical effects of an inpatient treatment at the Immanuel Hospital of Berlin, in the department for complementary and integrative medicine, with the use of a modified fasting regime. A pre- and post- as well as group comparisons are planned. Patients that are admitted to the inpatient department for metabolic syndrome, osteoarthritis of the hip or knee, rheumatoid arthritis and fibromyalgia will be enrolled in the study.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2018

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

December 20, 2018

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 24, 2018

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
Last Updated

May 12, 2021

Status Verified

May 1, 2021

Enrollment Period

4.1 years

First QC Date

December 20, 2018

Last Update Submit

May 10, 2021

Conditions

Keywords

fastingnatural therapiesprolonged fasting

Outcome Measures

Primary Outcomes (5)

  • Fibromyalgia Impact Questionnaire (FIQ)

    Questionnaire; The FIQ is scored in such a way that a higher score indicates a greater impact of the syndrome on the person. Each of the 10 items has a maximum possible score of 10. Thus the maximum possible score is 100. The average FM patient scores about 50, severely afflicted patients are usually 70 plus.

    Change Baseline, 2 weeks, 3 months, 6 months, 12 months

  • Disease Activity Score 28 (DAS 28)

    Questionnaire with Clinical Examination; Change from Baseline in the DAS-28, range from 2.0 to 10.0 while higher values meaning a higher disease activity and below of 2.6 meaning remission

    Change Baseline, 2 weeks, 3 months, 6 months, 12 months

  • Health Assessment Questionnaire (HAQ)

    Questionnaire; Change from Baseline in the HAQ, range from 0 to 3 while higher values meaning a higher grade of disability

    Change Baseline, 2 weeks, 3 months, 6 months, 12 months

  • Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    Questionnaire consisting of 24 items divided into 3 subscales: Pain (5items), Stiffness (2 items), Physical Function (17 items). The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Higher values meaning a higher grade of disability.

    Change Baseline, 2 weeks, 3 months, 6 months, 12 months

  • Summary of Diabetes Self Care Activities Measure (SDSCA)

    Questionnaire; 11 items with each item scored on a scale of 0-7.

    Change Baseline, 2 weeks, 3 months, 6 months, 12 months

Secondary Outcomes (16)

  • Pain on Visual Analogue Scale (VAS)

    Change Baseline, 2 weeks, 3 months, 6 months, 12 months

  • Hospital Anxiety and Depression Scale (HADS)

    Change Baseline, 2 weeks, 3 months, 6 months, 12 months

  • Perceived Stress Scale (PSS)

    Change Baseline, 2 weeks, 3 months, 6 months, 12 months

  • Quality of Life (WHO-5)

    Change Baseline, 2 weeks, 3 months, 6 months, 12 months

  • Body-Mass-Index (BMI)

    Change Baseline, 2 weeks

  • +11 more secondary outcomes

Interventions

The prolonged modified fasting is a dietary intervention with abstinence from solid foods and a caloric intake of 100-400 kcal through juices and vegetable broths

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Regular hospitalised patients

You may qualify if:

  • The patient is consents to participating in the trial during the first 24h of his or her stay in the inpatient naturopathic department of the Immanuel Hospital.
  • Written informed consent is given
  • The referral diagnosis is one of the following: diabetes mellitus type 2/metabolic syndrome, osteoarthritis of the hip, osteoarthritis of the knee, rheumatoid arthritis, fibromyalgia.

You may not qualify if:

  • Language barries to understanding the instructions of the study personnel
  • Dementia or other strong cognitive impairment
  • Pregnant or lactating women
  • Taking part in another study at the same time

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Immanuel Hospital

Wannsee, State of Berlin, 14109, Germany

Location

Related Publications (1)

  • Koppold DA, Kandil FI, Muller A, Guttler O, Steckhan N, Meiss S, Breinlinger C, Nelle E, Rajput Khokhar A, Jeitler M, Hanslian E, Fischer JM, Michalsen A, Kessler CS. Effects of Prolonged Medical Fasting during an Inpatient, Multimodal, Nature-Based Treatment on Pain, Physical Function, and Psychometric Parameters in Patients with Fibromyalgia: An Observational Study. Nutrients. 2024 Apr 4;16(7):1059. doi: 10.3390/nu16071059.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood, serum, urine

MeSH Terms

Conditions

Metabolic SyndromeOsteoarthritis, HipOsteoarthritis, KneeArthritis, RheumatoidFibromyalgiaFasting

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesOsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System DiseasesMuscular DiseasesNeuromuscular DiseasesNervous System DiseasesFeeding BehaviorBehavior

Study Officials

  • Andreas Michalsen, Prof. Dr.

    Study Principal Investigator

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 20, 2018

First Posted

December 24, 2018

Study Start

February 1, 2018

Primary Completion

March 1, 2022

Study Completion

March 1, 2022

Last Updated

May 12, 2021

Record last verified: 2021-05

Data Sharing

IPD Sharing
Will not share

Locations